Half-year report · HY
4543.TEDINET S100X3VY
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥534.9bn | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥1.04T | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥508.7bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥101.0bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥87.7bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥101.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥154.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥85.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥76.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥117.0bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥63.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥76.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥63.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.89T | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.83T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.75T | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥457.3bn | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥459.9bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.44T | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.37T | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.31T | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.33T | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥1.44T | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.37T | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.31T | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥217.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥221.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥194.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥204.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥102.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥210.8bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥100.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥71.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥82.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥38.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥38.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥108.8bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥65.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥52.13 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥79.01 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥42.57 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥52.12 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥78.99 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥42.56 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 75.9% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.8% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 75.0% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2025-04-01 → 2025-09-30 | ¥163m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥1.8bn |
| Blood And Cell Technologies Companyreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥107.1bn |
| Blood And Cell Technologies Companyreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥15.6bn |
| Cardiac And Vascular Companyreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥322.1bn |
| Cardiac And Vascular Companyreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥87.0bn |
| Medical Care Solutions Companyreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥105.6bn |
| Medical Care Solutions Companyreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥13.5bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥534.8bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥116.2bn |
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2024-09-30 | ¥132m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| Blood And Cell Technologies Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥98.0bn |
| Blood And Cell Technologies Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥13.2bn |
| Cardiac And Vascular Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥306.3bn |
| Cardiac And Vascular Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥76.9bn |
| Medical Care Solutions Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥104.3bn |
| Medical Care Solutions Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥12.7bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥508.6bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥102.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 630
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from issuance of bonds fin cf IFRS | InterimDuration | － | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1InterimDuration | -4001000000 | JPY |
| Repayments of lease obligations fin cf IFRS | InterimDuration | -3781000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1InterimDuration | -2248000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | InterimDuration | -1000000 | JPY |
| Decrease increase in deposits for purchase of treasury shares fin cf IFRS | Prior1InterimDuration | -7754000000 | JPY |
| Decrease increase in deposits for purchase of treasury shares fin cf IFRS | InterimDuration | － | JPY |
| Dividends paid fin cf IFRS | Prior1InterimDuration | -16331000000 | JPY |
| Dividends paid fin cf IFRS | InterimDuration | -19169000000 | JPY |
| Proceeds from settlement of derivatives fin cf IFRS | Prior1InterimDuration | 25420000000 | JPY |
| Proceeds from settlement of derivatives fin cf IFRS | InterimDuration | － | JPY |
| Net cash provided by used in financing activities IFRS | Prior1InterimDuration | -65398000000 | JPY |
| Net cash provided by used in financing activities IFRS | InterimDuration | -37951000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1InterimDuration | -6627000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | InterimDuration | 2255000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1InterimDuration | -9966000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | InterimDuration | -4717000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 204883000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 221872000000 | JPY |
| Cash and cash equivalents IFRS | Prior1InterimInstant | 194916000000 | JPY |
| Cash and cash equivalents IFRS | InterimInstant | 217155000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration_jpcrp040300-ssr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 306264000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration_jpcrp040300-ssr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 104278000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration_jpcrp040300-ssr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 98009000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration_ReportableSegmentsMember | 508552000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration_ReconcilingItemsMember | 132000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration | 508685000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_jpcrp040300-ssr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 76875000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_jpcrp040300-ssr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 12744000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_jpcrp040300-ssr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 13195000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_ReportableSegmentsMember | 102816000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_ReconcilingItemsMember | 1168000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration | 103984000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1InterimDuration_jpcrp040300-ssr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | -5084000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1InterimDuration_jpcrp040300-ssr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | － | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1InterimDuration_jpcrp040300-ssr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | -5622000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1InterimDuration_ReportableSegmentsMember | -10706000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1InterimDuration_ReconcilingItemsMember | -194000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1InterimDuration | -10901000000 | JPY |
| Non recurring profit or loss IFRS | Prior1InterimDuration | -5366000000 | JPY |
| Operating profit loss IFRS | Prior1InterimDuration | 87716000000 | JPY |
| Finance income IFRS | Prior1InterimDuration | 1758000000 | JPY |
| Finance costs IFRS | Prior1InterimDuration | 4197000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1InterimDuration | -137000000 | JPY |
| Profit loss before tax IFRS | Prior1InterimDuration | 85140000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 322053000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 105639000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 107074000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_ReportableSegmentsMember | 534766000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_ReconcilingItemsMember | 163000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |